Mineralys Therapeutics, Inc. Share Price & Technical Analysis
MLYS · $24.18 (+7.47%)
Healthcare / Biotechnology
$24.18
+7.47%
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and…
Price chart
Seasonality
Jun has 1 positive and 3 negative years (last 4 years shown)
-22% return in Jun, -2% avg return in past 3 year Jun month.
-40% return in 2026, 28% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -15% | -5% | -7% | -5% | 13% | -22% | – | – | – | – | – | – | -40% |
| 25 | -16% | -9% | 73% | -14% | 10% | -14% | 4% | 9% | 68% | 7% | 8% | -16% | 111% |
| 24 | 28% | 40% | -17% | -5% | 3% | -10% | 6% | 0% | -2% | 12% | -5% | -4% | 45% |
| 23 | – | -16% | -11% | -14% | 7% | 18% | -17% | -9% | -27% | -19% | -14% | 30% | -72% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.03B
P/E ratio
—
52W high
$47.65
52W low
$12.59
Volume
25,49,003
Beta
0.56
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹35,920
Abbott Laboratories Cede…
₹33,540
Eli Lilly And Company Ce…
₹30,700
Unitedhealth Group Inc C…
₹18,590
₹7,059
Frequently asked questions
- What is Mineralys Therapeutics, Inc. share price today?
- Mineralys Therapeutics, Inc. (MLYS) last traded around $24.18 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MLYS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MLYS. Download the app for real-time alerts.
- How can I analyze Mineralys Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.